Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

26 août 2020 18h05 HE | Source: Genmab A/S

Genmab Announces Late-Breaking Oral Presentation of Phase 2 innovaTV 204 Study at the ESMO Virtual Congress 2020

Media Release Copenhagen, Denmark, Aug 27, 2020 InnovaTV 204 study evaluated tisotumab vedotin in recurrent or metastatic cervical cancer Data from the study selected as a late-breaking abstract at...
20 août 2020 16h40 HE | Source: Genmab A/S

Genmab Announces Janssen Granted U.S. FDA Approval for DARZALEX® (daratumumab) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Company Announcement DARZALEX® (daratumumab) approved by U.S. FDA in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed/refractory multiple myeloma who...
20 août 2020 16h06 HE | Source: Genmab A/S

Genmab Announces Plan to Transition Arzerra® (ofatumumab) to an Oncology Access Program for Chronic Lymphocytic Leukemia Patients in the U.S.

Company Announcement Novartis intends to transition availability of Arzerra® (ofatumumab) to an oncology access program for chronic lymphocytic leukemia patients in the U.S. Genmab receives USD 30...
20 août 2020 13h33 HE | Source: Genmab A/S

U.S. FDA Approves Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis

Company Announcement Kesimpta® (ofatumumab) approved by U.S. FDA for the treatment of relapsing forms of multiple sclerosis in adultsFirst B-cell therapy that can be self-administered using...
18 août 2020 15h40 HE | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement Copenhagen, Denmark; August 18, 2020 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 62,716 shares as a consequence of the exercise of employee warrants. The...
12 août 2020 11h23 HE | Source: Genmab A/S

Genmab Announces Financial Results for the First Half of 2020

August 12, 2020; Copenhagen, Denmark; Interim Report for the First Half of 2020 Highlights ·Genmab and AbbVie enter into broad oncology collaboration; USD 750 million upfront payment with...
31 juil. 2020 15h38 HE | Source: Genmab A/S

Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Company Announcement Phase 3 APOLLO randomized study evaluating subcutaneous daratumumab in combination with pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in relapsed or...
20 juil. 2020 11h57 HE | Source: Genmab A/S

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; July 20, 2020 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital...
16 juil. 2020 06h43 HE | Source: Genmab A/S

Genmab Announces Net Sales of DARZALEX® for the Second Quarter of 2020

Company Announcement Net sales of DARZALEX® in the second quarter of 2020 totaled USD 901 millionGenmab will receive royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark;...
07 juil. 2020 07h01 HE | Source: Genmab A/S

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; July 7, 2020 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets...

Page précédente

Page suivante